Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

New insights into the impact of primary lung adenocarcinoma location on metastatic sites and sequence: A multicenter cohort study.

Klikovits T, Lohinai Z, Fábián K, Gyulai M, Szilasi M, Varga J, Baranya E, Pipek O, Csabai I, Szállási Z, Tímár J, Hoda MA, Laszlo V, Hegedűs B, Renyi-Vamos F, Klepetko W, Ostoros G, Döme B, Moldvay J.

Lung Cancer. 2018 Dec;126:139-148. doi: 10.1016/j.lungcan.2018.11.004. Epub 2018 Nov 5.

PMID:
30527178
2.

Achieving Thoracic Oncology data collection in Europe: a precursor study in 35 Countries.

Rich A, Baldwin D, Alfageme I, Beckett P, Berghmans T, Brincat S, Burghuber O, Corlateanu A, Cufer T, Damhuis R, Danila E, Domagala-Kulawik J, Elia S, Gaga M, Goksel T, Grigoriu B, Hillerdal G, Huber RM, Jakobsen E, Jonsson S, Jovanovic D, Kavcova E, Konsoulova A, Laisaar T, Makitaro R, Mehic B, Milroy R, Moldvay J, Morgan R, Nanushi M, Paesmans M, Putora PM, Samarzija M, Scherpereel A, Schlesser M, Sculier JP, Skrickova J, Sotto-Mayor R, Strand TE, Van Schil P, Blum TG.

BMC Cancer. 2018 Nov 20;18(1):1144. doi: 10.1186/s12885-018-5009-y.

3.

Afatinib restrains K-RAS-driven lung tumorigenesis.

Moll HP, Pranz K, Musteanu M, Grabner B, Hruschka N, Mohrherr J, Aigner P, Stiedl P, Brcic L, Laszlo V, Schramek D, Moriggl R, Eferl R, Moldvay J, Dezso K, Lopez-Casas PP, Stoiber D, Hidalgo M, Penninger J, Sibilia M, Győrffy B, Barbacid M, Dome B, Popper H, Casanova E.

Sci Transl Med. 2018 Jun 20;10(446). pii: eaao2301. doi: 10.1126/scitranslmed.aao2301.

PMID:
29925635
4.

Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients.

Rojkó L, Reiniger L, Téglási V, Fábián K, Pipek O, Vágvölgyi A, Agócs L, Fillinger J, Kajdácsi Z, Tímár J, Döme B, Szállási Z, Moldvay J.

J Cancer Res Clin Oncol. 2018 Jul;144(7):1219-1226. doi: 10.1007/s00432-018-2642-4. Epub 2018 Apr 19.

PMID:
29675791
5.

[Molecular diagnostics of ALK-positive lung cancer].

Tímár J, Lotz G, Rásó E, Moldvay J.

Magy Onkol. 2017 Sep 20;61(3):301-311. Epub 2017 Aug 1. Hungarian.

6.

Renal Impairment Hampers Bisphosphonate Treatment in a Quarter of Lung Cancer Patients with Bone Metastasis.

Fábián K, Puskás R, Kakuk T, Prés L, Fejes D, Szegedi Z, Rojkó L, Szállási Z, Döme B, Pipek O, Moldvay J.

Basic Clin Pharmacol Toxicol. 2017 Aug 21. doi: 10.1111/bcpt.12876. [Epub ahead of print]

7.

Renal Impairment Hampers Bisphosphonate Treatment in a Quarter of Lung Cancer Patients with Bone Metastasis.

Fábián K, Puskás R, Kakuk T, Prés L, Fejes D, Szegedi Z, Rojkó L, Szállási Z, Döme B, Pipek O, Moldvay J.

Basic Clin Pharmacol Toxicol. 2018 Jan;122(1):126-132. doi: 10.1111/bcpt.12854. Epub 2017 Aug 24.

PMID:
28730730
8.

Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis.

Téglási V, Reiniger L, Fábián K, Pipek O, Csala I, Bagó AG, Várallyai P, Vízkeleti L, Rojkó L, Tímár J, Döme B, Szállási Z, Swanton C, Moldvay J.

Neuro Oncol. 2017 Aug 1;19(8):1058-1067. doi: 10.1093/neuonc/now309.

9.

Breast carcinoma subtypes show different patterns of metastatic behavior.

Molnár IA, Molnár BÁ, Vízkeleti L, Fekete K, Tamás J, Deák P, Szundi C, Székely B, Moldvay J, Vári-Kakas S, Szász MA, Ács B, Kulka J, Tőkés AM.

Virchows Arch. 2017 Mar;470(3):275-283. doi: 10.1007/s00428-017-2065-7. Epub 2017 Jan 19.

PMID:
28101678
10.

KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis.

Lohinai Z, Klikovits T, Moldvay J, Ostoros G, Raso E, Timar J, Fabian K, Kovalszky I, Kenessey I, Aigner C, Renyi-Vamos F, Klepetko W, Dome B, Hegedus B.

Sci Rep. 2017 Jan 4;7:39721. doi: 10.1038/srep39721.

11.

Expression of mTORC1/2-related proteins in primary and brain metastatic lung adenocarcinoma.

Krencz I, Sebestyén A, Fábián K, Márk Á, Moldvay J, Khoor A, Kopper L, Pápay J.

Hum Pathol. 2017 Apr;62:66-73. doi: 10.1016/j.humpath.2016.12.012. Epub 2016 Dec 24.

PMID:
28025080
12.

Claudin-1 Protein Expression Is a Good Prognostic Factor in Non-Small Cell Lung Cancer, but only in Squamous Cell Carcinoma Cases.

Moldvay J, Fábián K, Jäckel M, Németh Z, Bogos K, Furák J, Tiszlavicz L, Fillinger J, Döme B, Schaff Z.

Pathol Oncol Res. 2017 Jan;23(1):151-156. doi: 10.1007/s12253-016-0115-0. Epub 2016 Sep 29.

PMID:
27687058
13.

Significance of Primary Tumor Location and Histology for Brain Metastasis Development and Peritumoral Brain Edema in Lung Cancer.

Fábián K, Gyulai M, Furák J, Várallyay P, Jäckel M, Bogos K, Döme B, Pápay J, Tímár J, Szállási Z, Moldvay J.

Oncology. 2016;91(5):237-242. Epub 2016 Aug 26.

PMID:
27562339
14.

[Self defense instead of offense - Immunotherapy in lung cancer].

Moldvay J, Ostoros G.

Magy Onkol. 2016 Mar 2;60(1):28-33. Epub 2016 Jan 6. Review. Hungarian.

15.

A robust prognostic gene expression signature for early stage lung adenocarcinoma.

Krzystanek M, Moldvay J, Szüts D, Szallasi Z, Eklund AC.

Biomark Res. 2016 Feb 19;4:4. doi: 10.1186/s40364-016-0058-3. eCollection 2016.

16.

Differences in the Epidemiology of Rare EGFR Mutations in Different Populations.

Lohinai Z, Ostoros G, Moldvay J, Dome B, Hegedus B.

J Thorac Oncol. 2016 Jan;11(1):e19-20. doi: 10.1016/j.jtho.2015.09.003. No abstract available.

17.

From Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic Small Cell Lung Cancer (SCLC).

Lohinai Z, Dome P, Szilagyi Z, Ostoros G, Moldvay J, Hegedus B, Dome B, Weiss GJ.

PLoS One. 2016 Jan 6;11(1):e0144797. doi: 10.1371/journal.pone.0144797. eCollection 2016.

18.

[Excerpts from the collaborative lung cancer research program of Semmelweis University, the National Institute of Oncology and Korányi Institute of TB and Pulmonology (2010-2015)].

Hegedûs B, Moldvay J, Berta J, Lohinai Z, Rózsás A, Cserepes MT, Fábián K, Ostoros G, Tóvári J, Rényi-Vámos F, Tímár J, Döme B.

Magy Onkol. 2015 Dec;59(4):282-5. Epub 2015 Nov 21. Hungarian.

19.

Reply to Rare Versus Artifactual EGFR Mutations.

Lohinai Z, Ostoros G, Moldvay J, Dome B, Hegedus B.

J Thorac Oncol. 2015 Aug;10(8):e80-1. doi: 10.1097/JTO.0000000000000591. No abstract available.

20.

Lung cancer drug therapy in Hungary - 3-year experience.

Moldvay J, Rokszin G, Abonyi-Tóth Z, Katona L, Fábián K, Kovács G.

Onco Targets Ther. 2015 May 13;8:1031-8. doi: 10.2147/OTT.S65794. eCollection 2015.

21.

Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma.

Lohinai Z, Hoda MA, Fabian K, Ostoros G, Raso E, Barbai T, Timar J, Kovalszky I, Cserepes M, Rozsas A, Laszlo V, Grusch M, Berger W, Klepetko W, Moldvay J, Dome B, Hegedus B.

J Thorac Oncol. 2015 May;10(5):738-46. doi: 10.1097/JTO.0000000000000492.

22.

Protein expression differences between lung adenocarcinoma and squamous cell carcinoma with brain metastasis.

Fábián K, Németh Z, Furák J, Tiszlavicz L, Pápay J, Krenács T, Tímár J, Moldvay J.

Anticancer Res. 2014 Oct;34(10):5593-7.

PMID:
25275061
23.

Decreased ERCC1 Expression After Platinum-Based Neoadjuvant Chemotherapy in non-Small Cell Lung Cancer.

Podmaniczky E, Fábián K, Pápay J, Puskás R, Gyulai M, Furák J, Tiszlavicz L, Losonczy G, Tímár J, Moldvay J.

Pathol Oncol Res. 2015 Apr;21(2):423-31. doi: 10.1007/s12253-014-9839-x. Epub 2014 Sep 7.

PMID:
25194563
24.

[Gefitinib treatment in lung cancer -- rebiopsy, retreatment, remission].

Moldvay J, Pápay J, Kovalszky I, Balázs G, Puskás R, Losonczy G.

Magy Onkol. 2014 Jun;58(2):133-7. Epub 2014 Mar 5. Hungarian.

25.

Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy.

Cserepes M, Ostoros G, Lohinai Z, Raso E, Barbai T, Timar J, Rozsas A, Moldvay J, Kovalszky I, Fabian K, Gyulai M, Ghanim B, Laszlo V, Klikovits T, Hoda MA, Grusch M, Berger W, Klepetko W, Hegedus B, Dome B.

Eur J Cancer. 2014 Jul;50(10):1819-28. doi: 10.1016/j.ejca.2014.04.001. Epub 2014 Apr 22.

26.

EGFR autophosphorylation but not protein score correlates with histologic and molecular subtypes in lung adenocarcinoma.

Moldvay J, Barbai T, Bogos K, Piurko V, Fillinger J, Popper HH, Tímár J.

Diagn Mol Pathol. 2013 Dec;22(4):204-9. doi: 10.1097/PDM.0b013e3182936957.

PMID:
24193009
27.

[Analysis of drug therapy of lung cancer in Hungary].

Moldvay J, Rokszin G, Abonyi-Tóth Z, Katona L, Kovács G.

Magy Onkol. 2013 Mar;57(1):33-8. doi: MagyOnkol.2013.57.1.33. Epub 2012 Dec 20. Hungarian.

28.

[Personalized therapy in non-small cell lung cancer: from diagnosis to therapy].

Moldvay J.

Orv Hetil. 2012 Jun 10;153(23):909-16. doi: 10.1556/OH.2012.29397. Review. Hungarian.

PMID:
22668592
29.

[EGFR tyrosine kinase inhibitors in lung cancer management: sensitivity and resistance].

Moldvay J, Peták I.

Magy Onkol. 2012 Mar;56(1):38-49. doi: MagyOnkol.2012.56.1.38. Epub 2012 Jan 15. Hungarian.

30.

[Examination of ERCC1 expression in lung cancer patients treated with platinum-based chemotherapy].

Moldvay J, Pápay J, Puskás R, Furák J, Losonczy G, Matolcsy A.

Magy Onkol. 2011 Jun;55(2):105-9. doi: MagyOnkol.2011.55.2.105. Epub 2011 Feb 7. Hungarian.

31.

[Incidence, risk factors and prevention of cisplatin-induced nephrotoxicity in patients with lung cancer].

Losonczy G, Máthé C, Müller V, Szondy K, Moldvay J.

Magy Onkol. 2010 Dec;54(4):289-96. doi: 10.1556/MOnkol.54.2010.4.3. Hungarian.

32.

Platinum-based chemotherapy in lung cancer affects the expression of certain biomarkers including ERCC1.

Pápay J, Sápi Z, Egri G, Gyulai M, Szende B, Losonczy G, Tímár J, Moldvay J.

Pathol Oncol Res. 2009 Sep;15(3):445-50. doi: 10.1007/s12253-009-9155-z.

PMID:
19253035
33.

Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry.

Pinter F, Papay J, Almasi A, Sapi Z, Szabo E, Kanya M, Tamasi A, Jori B, Varkondi E, Moldvay J, Szondy K, Keri G, Dominici M, Conte P, Eckhardt S, Kopper L, Schwab R, Petak I.

J Mol Diagn. 2008 Mar;10(2):160-8. doi: 10.2353/jmoldx.2008.070125. Epub 2008 Feb 7.

34.

[Financial aspects of targeted therapy of lung cancer as compared to conventional chemotherapy].

Moldvay J.

Magy Onkol. 2007;51(3):191-6. Epub 2007 Oct 7. Hungarian.

35.

Immunophenotypic profiling of nonsmall cell lung cancer progression using the tissue microarray approach.

Papay J, Krenacs T, Moldvay J, Stelkovics E, Furak J, Molnar B, Kopper L.

Appl Immunohistochem Mol Morphol. 2007 Mar;15(1):19-30.

PMID:
17536303
36.

Distinct claudin expression profile in histologic subtypes of lung cancer.

Moldvay J, Jäckel M, Páska C, Soltész I, Schaff Z, Kiss A.

Lung Cancer. 2007 Aug;57(2):159-67. Epub 2007 Apr 6.

PMID:
17418912
37.

Protocol modifications influence the result of EGF receptor immunodetection by EGFR pharmDx in paraffin-embedded cancer tissues.

Derecskei K, Moldvay J, Bogos K, Tímár J.

Pathol Oncol Res. 2006;12(4):243-6. Epub 2006 Dec 25.

38.

[Epidermal growth factor receptor (EGFR): therapeutic target in the treatment of lung adenocarcinoma].

Schwab R, Peták I, Pintér F, Szabó E, Kánya M, Tamási A, Várkondi E, Almási A, Szokolóczi O, Pápay J, Moldvay J, Kéri G, Kopper L.

Orv Hetil. 2005 Nov 13;146(46):2335-42. Review. Hungarian.

PMID:
16370245
39.

[The role of bronchoscopy in examination and treatment of esophageal tumours].

Varga I, Szucs MZ, Moldvay J, Jáger M, Szucs G, Bordás M, Molnár L, Szilasi M, Strausz J.

Orv Hetil. 2004 Nov 7;145(45):2285-8. Hungarian.

PMID:
15573892
40.

NT-brain natriuretic peptide levels in pleural fluid distinguish between pleural transudates and exudates.

Tomcsányi J, Nagy E, Somlói M, Moldvay J, Bezzegh A, Bózsik B, Strausz J.

Eur J Heart Fail. 2004 Oct;6(6):753-6.

41.

[Our experience using autofluorescence bronchoscopy].

Kovács G, Dulka E, Márk Z, Moldvay J, Morócz E, Putz Z, Strausz J.

Orv Hetil. 2004 Jul 11;145(28):1473-8. Hungarian.

PMID:
15366714
42.

The role of TTF-1 in differentiating primary and metastatic lung adenocarcinomas.

Moldvay J, Jackel M, Bogos K, Soltész I, Agócs L, Kovács G, Schaff Z.

Pathol Oncol Res. 2004;10(2):85-8. Epub 2004 Jun 9.

43.

[Tumor markers and prognostic factors of the primary lung cancer]

Moldvay J.

Magy Onkol. 2000 Oct 1;44(3):195-202. Hungarian.

44.

Predictive survival markers in patients with surgically resected non-small cell lung carcinoma.

Moldvay J, Scheid P, Wild P, Nabil K, Siat J, Borrelly J, Marie B, Farré G, Labib T, Pottier G, Sesboüé R, Bronner C, Vignaud JM, Martinet Y, Martinet N.

Clin Cancer Res. 2000 Mar;6(3):1125-34.

45.

Coexpression of p53 and tissue transglutaminase genes in human normal and pathologic adrenal tissues.

Adleff V, Rácz K, Szende B, Tóth M, Moldvay J, Varga I, Bezzegh A, Szegedi Z, Gláz E.

J Steroid Biochem Mol Biol. 1998 Jul;66(1-2):27-33.

PMID:
9712408
46.

P53 expression in stage I squamous cell lung cancer.

Moldvay J, Strausz J, Egerváry M, Agócs L, Bocsi J, Schaff Z.

Pathol Oncol Res. 1998;4(1):8-13.

47.

[In situ hybridization for the detection of hepatitis C virus RNA in mononuclear cells of peripheral blood from infected patients].

Moldvay J, Deny P, Pol S, Brechot C, Lamas E.

Orv Hetil. 1995 Oct 15;136(42):2267-71. Hungarian.

PMID:
7478469
48.

[Experience with transbronchial lung biopsy].

Szima B, Pápai Z, Kis S, Soltész I, Egerváry M, Moldvay J, Strausz J.

Orv Hetil. 1994 Aug 28;135(35):1919-21. Hungarian.

PMID:
8072764
49.
50.

Congenital osteogenesis imperfecta associated with arteriopathia calcificans infantum.

Moldvay J, Görbe E, Szende B, Papp Z.

Zentralbl Pathol. 1992 Jun;138(3):244-7.

PMID:
1525137

Supplemental Content

Loading ...
Support Center